Published in Cancer Weekly, June 10th, 2008
"Clinicopathological and follow-up data on 99 UC cases were reviewed and immunostained for HIF-1 alpha, CD68, vascular endothelial growth factor (VEGF) and CD34 antigen. Tumour-associated macrophage (TAM) counts and HIF-1 alpha expression were compared with clinicopathologic characteristics, overall survival (OS) and disease-free survival rates (DFS). High expression of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.